GABAB receptor agonist baclofen improves methamphetamine-induced cognitive deficit in mice.

Abstract

In this study, we investigated the effects of GABA(A) and GABA(B) receptor agonists on the methamphetamine-induced impairment of recognition memory in mice. Repeated treatment with methamphetamine at a dose of 1 mg/kg for 7 days induced an impairment of recognition memory. Baclofen, a GABA(B) receptor agonist, ameliorated the repeated methamphetamine-induced cognitive impairment, although gaboxadol, a GABA(A) receptor agonist, had no significant effect. GABA(B) receptors may constitute a putative new target in treating cognitive deficits in patients suffering from schizophrenia, as well as methamphetamine psychosis.

• Authors: Sawako Arai, Kazuhiro Takuma, Hiroyuki Mizoguchi, Daisuke Ibi, Taku Nagai, Hiroyuki Kamei, Hyoung-Chun Kim, Kiyofumi Yamada
• Journal: European journal of pharmacology (Eur J Pharmacol) Vol. 602 Issue 1 Pg. 101-4 (Jan 05 2009) ISSN: 1879-0712 [Electronic] Netherlands
• PMID: 19028488 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• GABA Agonists
• Methamphetamine
• Baclofen

Topics

• Animals
• Baclofen (pharmacology, therapeutic use)
• Cognition Disorders (chemically induced, drug therapy)
• Dose-Response Relationship, Drug
• GABA Agonists (pharmacology, therapeutic use)
• Male
• Memory (drug effects)
• Methamphetamine (adverse effects)
• Mice
• Mice, Inbred ICR
• Schizophrenia (drug therapy, physiopathology)
• Time Factors